UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Britain Courts Anthropic Amid US Defense Department Dispute 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Apple Turns 50: From Garage Startup to AI Crossroads 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
CANTON, Mass., Sept. 07, 2016 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at BioCentury’s 23rd Annual NewsMakers in the Biotech Industry Conference on Friday, September 9, 2016 at 10:30 a.m. Eastern Time. The conference will be held at Millennium Broadway Hotel, 145 West 44th Street, New York, NY.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
For Important Safety Information Visit, http://www.xtampzaer.com/
Contact: Douglas Carlson Vice President, Corporate Development [email protected]
